Nomegestrol Stragen (Nomegestrol Acetate)

Nomegestrol acetate is a progesterone receptor agonist. It binds to progesterone receptors in the hypothalamic‑pituitary‑ovarian axis, suppressing the luteinizing hormone surge and thereby preventing ovulation. It also induces secretory changes in the endometrium, creating conditions unsuitable for implantation.

The exact dose of Nomegestrol Stragen is determined by the prescribing clinician based on the indication, patient characteristics, and local guidelines. Healthcare professionals select the appropriate regimen and adjust it as needed; patients should follow the prescriber’s instructions precisely.

Nomegestrol Stragen is not intended for use during pregnancy because it is a hormonal contraceptive. If pregnancy occurs, the medication should be discontinued. Safety during breastfeeding has not been fully established, and clinicians usually advise caution or avoidance while nursing.

To order Nomegestrol Stragen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with combined estrogen‑progestin pills, Nomegestrol Stragen contains only a progestogen, which may reduce estrogen‑related side effects such as breast tenderness or nausea. It offers a once‑daily oral regimen and is suitable for women who cannot take estrogen, though efficacy and safety profiles are similar to other progestogen‑only options.

Store Nomegestrol Stragen tablets at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and ensure the packaging remains tightly closed until use.

Nomegestrol Stragen is taken orally, usually with a glass of water. The tablet is swallowed whole and should be taken at the same time each day to maintain consistent hormone levels. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe allergic reactions (anaphylaxis), and liver dysfunction indicated by elevated enzymes or jaundice. Patients should seek immediate medical attention if they experience symptoms suggestive of these conditions.

Contraindications include women with a history of thromboembolic disorders, active breast or endometrial cancer, severe liver disease, known hypersensitivity to nomegestrol acetate, or those who are pregnant. Clinicians should assess each patient’s medical history before initiating therapy.